Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
137 hedge funds and large institutions have $573M invested in Five Prime Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 31 reducing their positions, and 19 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 31
58% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 19
9% more funds holding
Funds holding: 126 → 137 (+11)
41% less call options, than puts
Call options by funds: $2.14M | Put options by funds: $3.64M
43% less capital invested
Capital invested by funds: $1B → $573M (-$428M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.6M |
| 2 |
DM
Deerfield Management
New York
|
+$14.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$12.6M |
| 5 |
Morgan Stanley
New York
|
+$9.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$36.4M |
| 2 |
HM
HealthCor Management
New York
|
-$29.3M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$9.2M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.18M |
| 5 |
Renaissance Technologies
New York
|
-$2.89M |
FPRX Hedge Fund Activity: Q4 2017 in Review
137 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2017, worth a combined $573M — down 43% from $1B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new FPRX positions and 19 closed out — a net gain of 11 holders — while 52 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $23.6M. The largest seller was Adage Capital Partners, cutting an estimated $36.4M.
- 137 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2017, up from 126 in Q3 2017.
- Funds reported $573M of Five Prime Therapeutics, Inc. stock for Q4 2017, down 43% quarter-over-quarter.
- 30 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2017 and 19 closed out, a net change of +11 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q4 2017 was State Street, an estimated $23.6M added.
- The largest Five Prime Therapeutics, Inc. seller in Q4 2017 was Adage Capital Partners, an estimated $36.4M sold.
Based on aggregated 13F filings for Q4 2017.